SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Hiroki SatoDaisuke KubotaHuan QiaoAchim JungbluthNatasha RekhtmanAdam J SchoenfeldHelena Alexandra YuGregory J RielyShinichi ToyookaChristine M LovlyPaul K PaikMarc LadanyiPang-Dian FanPublished in: JCO precision oncology (2022)
Our results demonstrate the therapeutic potential of SFK inhibition in primary tumorigenesis and AR driven by YES1/YAP1 signaling.